ReviewNanotheranostics2025
Metabolomics for the Identification of Biomarkers in Kidney Diseases.
Review in Nanotheranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A colorimetric sensor array based on merging silver nanozymes and gold nanoparticles for chronic kidney disease diagnosis and post-transplant monitoring.RSC advances · 2026Article
- Non-Oncology Biomarkers in Precision Medicine: A Narrative Review.Therapeutic innovation & regulatory science · 2026Review
- Lifestyles, metabolome and diabetic kidney disease: a cohort study.QJM : monthly journal of the Association of Physicians · 2026Article
- Gut microbiota-metabolite interactions in cisplatin-induced acute kidney injury in rats.BMC microbiology · 2026Article
- Metabolomics for Preclinical Detection of Diabetic Kidney Disease: A Comprehensive Review.International journal of molecular sciences · 2026Review
- Integration of digital physicalomics and dual-fluid metabolomics flux ratios reveals tubular secretory dysfunction in early diabetic kidney disease.Frontiers in endocrinology · 2026Article
- New Insights into the Role of Mitochondrial Dysfunction in Diabetic Kidney Disease in the Omics Era.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Serum and urinary golgi membrane protein 1 (GOLM1/GP73/G73) for chronic kidney disease staging.Frontiers in medicine · 2026Article
- S100A8/A9 in Kidney Diseases: Mechanisms, Spatiotemporal Regulation, Biomarker Potential, and Therapeutic Implications.Journal of inflammation research · 2026Review
- Dietary antioxidants and mortality in early-stage CKM syndrome: insights from NHANES.Nutrition & metabolism · 2025Article
- Study on Predictive Models for Differential Diagnosis of Diabetic Kidney Disease and Non-Diabetic Kidney Disease Based on Clinical and Biochemical Indicators.International journal of medical sciences · 2025Article
- Metabolomic profiling in a rat model of visual fatigue associated with liver-kidney yin deficiency syndrome.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the apparent rise in lifestyle-related changes, there has been a significant decline in renal health. Metabolomics plays a crucial role in the prognosis, diagnosis, and treatment of various renal conditions, including chronic kidney disease, acute kidney injury, diabetic kidney disease, kidney cancer, and post-transplant complications. Metabolomics has identified novel biomarkers, providing insights into altered pathways and potential therapeutic targets for kidney diseases. Kidney diseases and metabolomics keywords were searched in correspondence with the assigned keywords, including chronic kidney diseases, acute kidney injury, kidney carcinoma, kidney transplant, and diabetic kidney diseases on literature search engines. The applicable studies from this search were extracted and included in the study. This review is focused on the biomarkers identified in different kidney diseases such as chronic kidney diseases, acute kidney injury, diabetic kidney disease, kidney carcinoma and kidney transplant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.